Evusheld long-acting antibody combination approved for prevention and treatment of COVID-19 in Japan
First global approval for Evusheld as a COVID-19 treatment. PROVENT Phase III prevention trial showed reduced risk of developing symptomatic COVID-19. TACKLE Phase III treatment trial showed reduced risk of severe COVID-19 or death in high-risk patients.AstraZeneca's Evusheld (tixagevimab and cilgavimab, formerly AZD7442), a long-acting antibody combination, has been approved in Japan for both prevention (pre-exposure prophylaxis) and treatment of symptomatic disease caused by SARS-CoV-2 infection. The decision marks the first global marketing approval for Evusheld as a treatment for COVID-